IQV vs TMO
IQVIA and Thermo Fisher Scientific, both Healthcare
Thermo Fisher Scientific is the larger company at $245B against $43B. On trailing earnings IQV is the cheaper of the two at a P/E of 32.5 against 35.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year IQV returned +40% against +38% for TMO. The RyuScore puts IQV ahead, 66 against 46 out of 100.
| Figure | IQV | TMO |
|---|---|---|
| Last close | $262 | $662 |
| Market cap | $43B | $245B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 32.5 | 35.6 |
| Dividend yield | n/a | 0.3% |
| 1-year return | +40% | +38% |
| 5-year return | +1.8% | +19% |
| RyuScoresector-relative, 1–10 | 66/100 | 46/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Thermo Fisher Scientific
Revenue of $12B in Q2 2026, net income $1.7B. Its largest reported line is Life Sciences Solutions, 38% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.